BWXT, NorthStar Collaborate on Medical Isotope Production

BWXT Medical, a BWX Technologies business, will produce actinium-25 medical isotopes with NorthStar Medical Radioisotopes under a new master services agreement to advance cancer cell treatment.

Under the deal, the two businesses will collaborate in processing and purifying radium-226. The MSA also covers potential target design projects and exploration of opportunities to ensure backup supplies for both companies’ customers.

BWXT said NorthStar will extend its expertise in developing, producing, and commercializing radiopharmaceuticals as part of the collaboration.

Jonathan Cirtain, president and CEO of BWXT Medical and a 4×24 member, said the agreement with NorthStar is part of the company’s mission to provide high-quality medical isotopes to health care providers and patients. He added that the collaboration will accelerate the effort and ensure the expansion of actinium-225 production.

According to NorthStar CEO and President Frank Scholz, the agreement pushes the delivery of novel therapies to patients who need them.

In June, the BWXT subsidiary submitted its drug master file with the U.S. Food and Drug Administration for actinium-225, which kills cancer cells without impacting healthy tissues.